The report of the 20th National Congress of the Communist Party of China pointed out that we should speed up the construction of a new development pattern and focus on promoting high-quality development. ESG, as an important grasp to promote green development and achieve high-quality development, has been highly concerned by regulatory authorities and capital markets, and has become an important standard to measure the value of enterprises. Looking back on 2022, Shanghai Pharmaceutical focused on upgrading high-quality ESG credit, strengthened ESG capacity building, upgraded social responsibility report to sustainable development report for the first time, and won many awards for its outstanding ESG performance, which was widely recognized by many parties.

Six ESG Awards Witness the Milestone of Sustainable Development of Shanghai Pharmaceutical

Recently, the latest ESG rating results released by Morgan Stanley Capital International (hereinafter referred to as "MSCI"), an authoritative international index institution, show that Shanghai Pharmaceutical Group Co., Ltd. (Hereinafter referred to as "Shanghai Pharmaceutical" or "Company", stock code: 601607. 02607. (HK) MSCI's ESG rating rose from a to AA, a record high, ranking among the leading echelons in the global industry.

Since this year, with its sustained efforts and outstanding performance in ESG and sustainable development, Shanghai Pharmaceutical has stood out from many important awards and selections. It has successfully won many important awards, including the "ESG Excellent Practice Case of A-share Listed Companies" of the China Association of Listed Companies, the "Sustainable China Industrial Development Action" of the APEC China Business Council in 2022, and the Fortune China ESG Influence List. Many honors and commendations reflect the full affirmation and recognition of professional institutions at home and abroad and all sectors of society for Shanghai Pharmaceutical to actively fulfill its social responsibility, practice ESG concept and adhere to sustainable development for a long time, and highlight the leading ESG practice level of Shanghai Pharmaceutical in the pharmaceutical industry.

Shanghai Pharmaceutical 2022 ESG Honors List

Selected by China Association of Listed Companies 2022 "ESG Excellent Practice Cases of Listed Companies" and won the "ESG Best Practice Cases of A-share Listed Companies"

In September 2022, in order to promote listed companies to better implement the "double carbon" goal and do a good job in ESG related work, the China Association of Listed Companies organized the annual ESG Excellent Practice Case Collection and the publication of "ESG Excellent Practice Case of Listed Companies". ESG Excellent Practice Cases of Listed Companies collects 146 excellent cases from 28 industries, fully demonstrating the experience and practices of representative listed companies in ESG management, practice, information disclosure and other fields.

On the basis of excellent cases, the ESG Professional Committee of the Association organized two rounds of expert reviews based on 20 first-level indicators in four dimensions, and finally selected 30 ESG best practice cases of A-share listed companies. The association will issue certificates to the selected listed companies and record them in the positive list of the integrity archives database of the securities and futures market of the SFC. By virtue of its outstanding performance, Shanghai Pharmaceutical was selected as the "ESG Excellent Practice Case of Listed Companies" and won the "ESG Excellent Practice Case of A-share Listed Companies".

Ranked on the 2022 Fortune China ESG Influence List

On August 23, the Chinese website of Fortune released the first list of ESG influence in China. A total of 40 enterprises were selected in the list. Shanghai Pharmaceutical was honored for its unremitting efforts and outstanding performance in environment, society and governance for a long time.

Selected as the industrial case of "China Sustainable Industrial Development Action" of APEC China Business Council in 2022

On November 3, the 2022 APEC Business Leaders China Forum was held in Beijing. At the same time, the APEC China Business Council released the "Sustainable China Industrial Development Action" (hereinafter referred to as the "Action") industrial case in 2022. "Action" is guided by "Global Vision, China Sample", through carrying out special research, excavating industrial cases of green development and inclusive growth, demonstrating the positive attitude and practical action of Chinese business community in promoting sustainable development, refining and sharing the Chinese model of sustainable development. Shanghai Pharmaceutical was successfully selected as a leading enterprise in the pharmaceutical industry.

Won the "ESG Practice Case of the Year" award of the Interface Gold Medal

On September 8, the "ESG Practice Case of the Year" award was announced in the annual selection of the 2022 [Gold Medal Award] sponsored by Shanghai Newspaper Group | Interface News and supported by Shanghai Lingcan ESG Research Institute. In this selection, awards related to ESG information disclosure are added, and the selection focuses on "long-term doctrine" and the concept of high quality and sustainability. After several months of selection, a total of 10 enterprises were finally awarded the Golden Medal "ESG Practice Case of the Year", and Shanghai Pharmaceutical was successfully selected by virtue of its outstanding performance.

Awarded "ESG Competitiveness TOP20 of Chinese Pharmaceutical Listed Companies in 2022" by E Pharmaceutical Manager

In October 2022, E Pharmaceutical Manager released the "ESG Competitiveness and ESG Investment Value List of Chinese Pharmaceutical Listed Companies". This selection focused on the two dimensions of "ESG Transparency Evaluation" and "ESG Management Performance Evaluation", and evaluated about 150 qualified samples of Chinese Pharmaceutical A-share and H-share listed companies. As a leading enterprise in the pharmaceutical industry, Shanghai Pharmaceutical has successfully entered the list.

In-depth implementation of ESG concept to promote high-quality sustainable development

As a leading pharmaceutical enterprise in China, Shanghai Pharmaceutical shoulders the lofty mission of "persevering in improving people's healthy quality of life", adhering to the vision of "becoming a respected leading brand pharmaceutical manufacturer and health service provider with industry reputation", and has long integrated the concept of sustainable development into the company's daily operation and management. Pursue the balance of environmental, economic and social values, constantly improve the governance system of sustainable development and enhance governance capacity.

Shanghai Pharmaceutical has issued social responsibility reports for 12 consecutive years, and actively presents the progress and achievements of the company's work in fulfilling its social responsibility to stakeholders every year. In 2021, the company upgraded its 12th social responsibility report to a sustainable development report for the first time, presenting the company's efforts and performance in environmental, social and governance aspects more comprehensively, and demonstrating the company's commitment and vision to achieve sustainable development.

In terms of fulfilling its social responsibility, Shanghai Pharmaceutical actively responds to the national biomedical development strategy, adheres to the driving force of scientific and technological innovation, constantly innovates pharmaceutical products, pharmaceutical supply chain products and extended medical services, meets the growing new needs of customers, patients and other parties, and contributes to the healthy China strategy. In terms of drugs for rare diseases, Shanghai Pharmaceutical is one of the enterprises with the largest number of approvals for drugs for rare diseases in China. There are 21 varieties of products used for the treatment of rare diseases, involving 34 rare diseases. The company's rare disease business platform company, Shangyao Ruier, has laid out more than 20 rare disease drug product pipelines in the way of "autonomy + cooperation + introduction", continuously enriching the rare disease drug product matrix and filling the gap in China's rare disease drug market. In terms of building an innovation platform, Shanghai Pharmaceutical actively plays a leading role in building a major scientific and technological innovation research and development platform in 2021, and establishes a Shanghai Biomedical Frontier Industry Innovation Center, aiming at adopting the operation mode of "self-research + incubation" and bringing together "famous schools", "famous enterprises" and "famous institutes" in Shanghai,payingg attention to the early innovation projects with high demand for original innovation transformation and high market scarcity, and promoting the original innovation of Chinese biomedicine. In terms of mode innovation, the company has created a cloud health platform for medicine, creating a new retail mode of prescription drugs with electronic prescription circulation as the core and "Internet +" as the "service to patients". At the same time, the company has created a new mode of innovative medical payment of "Internet + medicine + medicine + insurance" through magnesium health, which has broken through the boundaries of patients, pharmaceutical companies and commercial insurance companies, and promoted the deep integration of financial instruments and medical fields, thus reducing the financial burden of patients and improving the accessibility of some drugs.

For a long time, Shanghai Pharmaceutical has been actively engaged in charity and public welfare undertakings, deeply engaged in public welfare fields such as health care, popular science education, culture and art, insisting on being an excellent corporate citizen, assuming corporate social responsibility, and giving back to the society, the people and the country. Over the years, it has persisted in carrying out various public welfare activities, forming a series of public welfare brands such as "Millions of Citizens Look at Xinyi", "Guofeng Health Travel", "Let Me @ You" Rare Disease Assistance, and participating in and sponsoring social welfare projects such as "Silver Snake Award" all the year round. In 2021, the total amount of charitable donations of the company reached 44.9665 million yuan.

Since the outbreak of COVID-19, Shanghai Pharmaceutical has thoroughly implemented the deployment of the CPC Central Committee, the State Council and the Shanghai Municipal Government on epidemic prevention and control, and devoted all efforts to the fight against COVID-19 in Shanghai and many parts of the country. Nearly 50,000 employees of enterprises at all levels, from R & D, production, distribution, logistics and distribution to pharmaceutical retail, have been racing against time. Implement all kinds of anti-epidemic and supply guarantee work with dedication, professional knowledge and efficient implementation. In 2020 alone, the total value of donated medical equipment, anti-epidemic drugs, protective supplies and other epidemic prevention materials exceeded 26 million yuan. In 2021, Shangyao Kangxinuo obtained the first approval for the production of COVID-19 vaccine in Shanghai, creating the "Shanghai speed" of establishment, completion and production in the same year.

In recent years, the company has also fully implemented the precise poverty alleviation policy and supported the strategy of rural revitalization. The subordinate enterprises have paired up with Shijia Village of Midu County, Dali Prefecture, Yunnan Province, Pioneer Village of Yili Town and Kanglang Village of Niujie Township to carry out the action of "100 Enterprises Helping 100 Villages" and "100 Enterprises Forming 100 Villages" of SASASAC in Shanghai, and jointly help the counterpart areas to take a solid step from poverty alleviation to rural revitalization. By the end of 2021, a total of 48 poverty alleviation and revitalization projects have been implemented in the past three years, including infrastructure construction, education support, cultivation of traditional Chinese medicines, love supermarkets and love breakfast (lunch) meals, with an investment of more than 12.8 million yuan, benefiting more than 14000 people (including more than 6400 poor people).

While actively assuming social responsibility, Shanghai Pharmaceutical attaches great importance to fulfilling its environmental responsibility. The 20th National Congress of the Communist Party of China pointed out that we should promote green development and promote the harmonious coexistence of man and nature. With the goal of "becoming a resource-saving and environment-friendly group company", Shanghai Pharmaceutical practices the concept of green low-carbon in all aspects of production, operation and management, and promotes the comprehensive green low-carbon transformation of China's economy and society. By the end of 2021, 4 enterprises under the company have been listed as pilot enterprises of carbon emissions trading in Shanghai, 5 enterprises have implemented photovoltaic projects, 23 enterprises have passed ISO14001 certification, 15 enterprises have passed ISO50001 certification, 6 enterprises have been rated as national green factories, and 4 enterprises have been rated as provincial and municipal green factories.

With the continuous advancement of the Healthy China Strategy and the National Double Carbon Strategy, in the future, Shanghai Pharmaceutical will continue to uphold the mission of "persevering in improving people's healthy living standards", continuously improve the level of ESG governance and the concept of sustainable development, and contribute to the promotion of high-quality sustainable development of industry and society.

Photo Source: Shanghai Pharmaceutical Group Official Website

党的二十大报告指出，要加快构建新发展格局，着力推动高质量发展。ESG作为推动绿色发展和实现高质量发展的重要抓手，受到了监管部门及资本市场的高度关注，成为衡量企业价值的重要标准。回顾2022年，上海医药聚焦高质量ESG信披升级，加强ESG能力建设，首次将社会责任报告升级为可持续发展报告，并凭借优异的ESG表现荣揽多项大奖，广获多方认可。

六大ESG奖项 见证上海医药可持续发展里程碑

近日，国际权威指数机构摩根士丹利资本国际公司（以下简称“MSCI”）公布的最新ESG评级结果显示，上海医药集团有限公司（以下简称“上海医药”或“公司”，股票代码：601607.SH，02607.HK）MSCI的 ESG评级从A级上升至AA级，创历史新高，跻身全球同行业领先梯队。

今年以来，凭借在ESG及可持续发展方面的持续努力和优异表现，上海医药已从多个重要奖项与评选中脱颖而出，成功揽获了包括中国上市公司协会“A股上市公司ESG优秀实践案例”、APEC中国工商理事会“可持续中国产业发展行动”2022年度产业案例、《财富》中国ESG影响力榜在内的多个重磅奖项。诸多荣誉与表彰体现了国内外专业机构及社会各界对上海医药长期以来积极履行社会责任、践行ESG理念、坚持可持续发展的充分肯定和认可，彰显了上海医药在医药行业中的领先ESG实践水平。

上海医药2022年 ESG荣誉一览

入选中国上市公司协会2022年《上市公司ESG优秀实践案例》并荣获“A股上市公司ESG最佳实践案例”

2022年9月，为推动上市公司更好落实“双碳”目标，做好ESG相关工作，中国上市公司协会组织开展年度ESG优秀实践案例征集及《上市公司ESG优秀实践案例》出版活动。《上市公司ESG优秀实践案例》汇集了来自 28 个行业的146 篇优秀案例，充分展示了各行业代表性上市公司在ESG管理、实践、信息披露等多个领域的经验与做法。

在优秀案例的基础上，协会ESG专业委员会依据四大维度20个一级指标、组织两轮专家评审，最终选出30家A股上市公司ESG最佳实践案例。协会将对入选上市公司颁发证书，并记入证监会证券期货市场诚信档案数据库正面清单。上海医药凭借优异表现入选了《上市公司ESG优秀实践案例》并荣获“A股上市公司ESG优秀实践案例”。

荣登2022年《财富》中国ESG影响力榜

8月23日，财富中文网重磅发布《财富》首份中国ESG影响力榜单，此次榜单共评选出40家企业，上海医药凭借长期以来在环境、社会及治理方面的不懈努力和优异表现，荣誉登榜。

入选APEC中国工商理事会“可持续中国产业发展行动”2022年度产业案例

11月3日，2022年APEC工商领导人中国论坛在北京举办。同期，APEC中国工商理事会发布了“可持续中国产业发展行动”（以下简称“行动”）2022年度产业案例。“行动”以“全球视野，中国样本”为导向，通过开展专项课题研究，挖掘绿色发展和包容性增长的产业案例，展现中国工商界推进可持续发展的积极态度与务实行动，提炼和分享可持续发展中国模式。上海医药作为医药行业领先企业成功入选。

荣膺界面金勋章“年度ESG实践案例”奖项

9月8日，由上海报业集团|界面新闻主办、上海领灿ESG研究院作为技术支持的2022【金勋章奖】年度评选揭晓了“年度ESG实践案例”奖。本次评选特别新增与ESG信息披露相关的奖项评选，并在评选中着重关注“长期主义”，关注高质量、可持续的理念。经过数月的遴选，最终共有10家企业获得金勋章“年度ESG实践案例”，上海医药凭借优异表现成功入选。

获评E药经理人“2022中国医药上市公司ESG竞争力TOP20”

2022年10月，E药经理人发布《中国医药上市公司ESG竞争力与ESG投资价值榜单》，本次评选关注“ESG透明度评价”与“ESG管理绩效评价”两大维度，对符合条件的约150家中国医药A、H股上市公司样本开展评估。上海医药作为医药行业领先企业成功登榜。

深入践行ESG理念 推动高质量可持续发展

上海医药作为国内医药龙头企业，肩负着“持之以恒  致力于提升民众的健康生活品质”的崇高使命，秉承“成为受人尊敬、具有行业美誉度的领先品牌药制造商和健康领域服务商”的愿景，长期以来将可持续发展理念融入公司日常运营与管理，积极履行社会责任，追求环境、经济与社会价值的平衡，不断完善可持续发展治理体系、提升治理能力。

上海医药已连续12年发布社会责任报告，每年主动向利益相关方呈现公司在履行社会责任方面的工作进度及成果。2021年公司首次将第12份社会责任报告升级为可持续发展报告，更全面地呈现公司在环境、社会及管治方面的努力和表现，展现公司实现可持续发展的承诺与愿景。

在履行社会责任方面，上海医药积极响应国家生物医药发展战略，坚持以科技创新为驱动，不断创新医药产品、医药供应链产品以及医疗延伸服务，满足客户、患者等各方日益增长的新需求，助力健康中国战略。在罕见病药物方面，上海医药是国内拥有罕见病药品批文最多的企业之一，产品中被用于治疗罕见病的共有21个品种，涉及34个罕见病病症。公司旗下罕见病业务平台公司上药睿尔，以“自主+合作+引进”的方式已布局超过20个罕见病药产品管线，持续丰富罕见病药产品矩阵，填补中国罕见病药物市场空白。在打造创新平台方面，上海医药积极发挥龙头企业带动作用，于2021年联合多方共同建设重大科技创新研发平台，设立上海生物医药前沿产业创新中心，旨在采取“自研+孵化”的运营模式，汇聚上海市“名校”“名企”“名院”尖端科研力量，关注对原始创新转化需求高、市场稀缺度高的早期创新项目，助推中国生物医药的原始创新。在模式创新方面，上海医药打造上药云健康平台，开创了以电子处方流转为核心，借力“互联网+”打造“服务到患者”的处方药新零售模式；同时，公司通过镁信健康创立了“互联网+医+药+险”的创新医疗支付新模式，打通了患者、药企以及商保公司的界限，推动金融工具与医疗领域的深度融合，从而减轻患者的经济负担，提高部分药品的可及性。

上海医药长期以来积极投身慈善公益事业，深耕医疗健康、科普教育、文化艺术等公益领域，坚持做优秀企业公民，承担企业社会责任，回馈社会、人民和国家。多年来坚持开展形式多样的公益活动，形成“百万市民看信谊”“国风健康行”“让我@你”罕见病援助等一系列公益品牌，常年参与及赞助支持“银蛇奖”等社会公益项目。2021年，本公司慈善捐赠总额达到 4496.65万元。

新冠疫情暴发以来，上海医药深入落实党中央、国务院及上海市委市政府关于疫情防控工作部署，全力以赴投入到上海和全国多地抗击新冠疫情的战斗中，公司上下从研发、生产、分销、物流配送到医药零售的各级企业近五万名员工与时间赛跑，以敬业的精神、专业的知识、高效的执行落实各项抗疫保供工作。仅 2020年一年，累计捐赠医疗设备、抗疫药品、防护用品等防疫物资价值就超过2600万元。2021年，上药康希诺获得上海首张新冠疫苗生产批件，创造当年成立、当年建成、当年投产的“上海速度”。

公司近年来还全面贯彻精准扶贫政策，支持乡村振兴战略。下属企业与云南省的大理州弥渡县弥城镇石甲村、苴力镇先锋村、牛街乡康朗村结对帮扶，深入开展上海市国资委“百企帮百村”“百企结百村”行动，共同助力对口帮扶地区迈出从脱贫攻坚到乡村振兴的坚实步伐。截至2021年末，近三年累计实施基础设施建设、教育支持、中药材种植、爱心超市、爱心早（午）餐等扶贫与振兴项目48项，投入资金1280余万元，受益群众14000余人（其中贫困人口6400余人）。

上海医药在积极承担社会责任的同时，高度重视履行环境责任。党的二十大指出，要推动绿色发展，促进人与自然和谐共生。上海医药以“成为一个资源节约型和环境友好型集团公司”为目标，在生产运营管理各个环节践行绿色低碳理念，助力我国经济社会全面绿色低碳转型。截至2021年末，公司下属4家企业被列入上海市碳排放交易试点企业，5家企业已实施光伏项目，23家企业通过ISO14001认证，15家企业通过ISO50001认证，6家企业被评为国家级绿色工厂，4家企业被评为省市级绿色工厂。

随着健康中国战略及国家双碳战略的不断推进，未来，上海医药将继续秉承“持之以恒 致力于提升民众的健康生活水平”的使命，持续提升ESG治理水平，贯彻可持续发展理念，为推动产业及社会高质量可持续发展贡献力量。